Stoke Therapeutics, Inc. (STOK) 8-K Current Report: March 3, 2026
Filed: March 3, 2026
Health Care
Pharmaceutical PreparationsStoke Therapeutics, Inc. (STOK) 8-K current report filed with SEC EDGAR on March 3, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 5.02: Departure/Election of Directors or Officers
Stoke Therapeutics, Inc. 8-K Mar 3, 2026 Event Analysis
Item 5.02 · Departure/Election of Directors or Officers
- • CEO Ian F. Smith awarded discretionary bonus of $697,125 for 2025 performance
- • Bonus equals 100% of his target annual bonus, despite not participating in standard 2025 program
- • Board scored corporate goals at 150% of target — signals strong 2025 clinical and financial execution
- • Smith appointed interim CEO March 2025, elevated to permanent CEO October 2025 — bonus covers full year contribution
Get deeper insights on Stoke Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.